RenovoRx grants 128,550 stock options to CCO

RenovoRx, Inc. reported that Chief Clinical Officer Leesa Gentry received a grant of stock options to purchase up to 128,550 shares of common stock at an exercise price of $0.98 per share.

Rhea-AI Filing Summary

RenovoRx, Inc. reported that Chief Clinical Officer Leesa Gentry received a grant of stock options to purchase up to 128,550 shares of common stock at an exercise price of $0.98 per share. The options vest over four years at a rate of 1/48 per month, with vesting starting on January 1, 2026, and becoming fully vested on January 1, 2030.

The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this grant, Gentry holds 128,550 stock options directly.

Insider Trade Summary

Grant/Award: 128,550 shares

Grant/Award 1 txn

Insider Gentry Leesa

Role Chief Clinical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	128,550	$0.00	$0.00

Holdings After Transaction: Stock Option — 128,550 contracts (Direct)

Footnotes (1)

1. F1. On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

Key Figures

Stock options granted: 128,550 options Exercise price: $0.98 per share Incentive stock options portion: 66,954 options +4 more

7 metrics

Stock options granted 128,550 options Grant to Chief Clinical Officer on April 3, 2026

Exercise price $0.98 per share Exercise price for granted stock options

Incentive stock options portion 66,954 options Underlying incentive stock options within total grant

Non-qualified stock options portion 61,596 options Underlying non-qualified stock options within total grant

Vesting schedule 1/48 per month over 4 years Monthly vesting beginning January 1, 2026

Full vesting date January 1, 2030 Date options become fully vested

Expiration date April 3, 2036 Date options expire if unexercised

Key Terms

incentive stock options, non-qualified stock options, vesting, effective registration statement, +1 more

5 terms

incentive stock options financial

"66,954 shares of which are underlying incentive stock options"

Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.

non-qualified stock options financial

"61,596 of which are underlying non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

vesting financial

"such options vesting over four years at a rate of 1/48 per month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

effective registration statement regulatory

"options will only become exercisable when there is an effective registration statement"

An effective registration statement is a company filing that a securities regulator has approved as meeting disclosure rules, giving the company the legal green light to sell new shares or debt to the public. For investors it matters because the approval signals needed information has been made public and allows offerings that can change a company's cash position, share count and stock liquidity—think of it as a permit that lets a fundraising or public sale go forward.

expiration financial

"options will become fully vested on January 1, 2030, and will expire on April 3, 2036"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RenovoRx (RNXT) report for Leesa Gentry?

RenovoRx reported that Chief Clinical Officer Leesa Gentry received a grant of 128,550 stock options. These options give her the right to purchase common shares at a fixed exercise price, subject to vesting and registration conditions over several years.

What are the key terms of Leesa Gentry’s RenovoRx (RNXT) stock option grant?

The grant covers options to buy 128,550 RenovoRx common shares at $0.98 per share. The options vest monthly over four years, start vesting January 1, 2026, fully vest January 1, 2030, and expire April 3, 2036, if not exercised.

How do the RenovoRx (RNXT) stock options for Leesa Gentry vest over time?

The options vest over four years at a rate of 1/48 each month, with no initial cliff. Vesting begins effective January 1, 2026, and continues monthly until the options are fully vested on January 1, 2030, assuming continued service.

When can Leesa Gentry exercise her RenovoRx (RNXT) stock options?

The options become exercisable only when an effective registration statement covers the underlying shares. Even after vesting, this registration condition must be satisfied before she can exercise and purchase the common stock.

What types of stock options did RenovoRx (RNXT) grant to Leesa Gentry?

The grant consists of 128,550 options split between 66,954 incentive stock options and 61,596 non-qualified stock options. Both types share the same $0.98 exercise price, vesting schedule, registration condition, and April 3, 2036 expiration date.

How many RenovoRx (RNXT) stock options does Leesa Gentry hold after this grant?

After this transaction, Leesa Gentry holds 128,550 RenovoRx stock options directly. These represent her total derivative holdings reported in this filing and are subject to vesting, registration effectiveness, and the stated expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gentry Leesa

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CALIFORNIA 94040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Clinical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.98	04/03/2026		A		128,550		(1)	(1)	Common Stock	128,550	$0	128,550	D

Explanation of Responses:

1. On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.

	/s/ Leesa Gentry	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)